Signs and Artifacts in Amyloid PET.

Radiographics

From the Department of Medical Imaging, University of Arizona/Banner University Medical Center, 1501 N Campbell Ave, PO Box 245067, Tucson, AZ 85724-5128 (T.F.L., N.E., P.H.K.); Institute for Neurodegenerative Disorders, New Haven, Conn (J.P.S.); Mallinckrodt Institute of Radiology, Washington University School of Medicine, St Louis, Mo (M.F.C.); and Departments of Medicine and Biomedical Engineering, University of Arizona, Tucson, Ariz (P.H.K.).

Published: September 2019

Establishing a diagnosis of Alzheimer dementia can be challenging, particularly early in the course of the disease. However, with disease-modifying therapies on the horizon, it is becoming increasingly important to achieve the correct diagnosis as soon as possible. In challenging presentations of dementia, such as patients with clinically atypical features or early-age onset of mild cognitive impairment, amyloid PET is a valuable tool in determining the diagnosis of Alzheimer dementia. Furthermore, preliminary data show that amyloid PET findings alter clinical management in patients who meet the appropriate use criteria. There are currently three U.S. Food and Drug Administration (FDA)-approved fluorine 18 (F)-labeled radiopharmaceuticals that allow in vivo detection of cerebral amyloid deposition, which is a hallmark pathologic feature of Alzheimer dementia. Knowledge of the common imaging features among these three F-labeled radiopharmaceuticals in the normal and abnormal brain will enable the radiologist to more accurately interpret amyloid PET studies. As in other subspecialties of radiology, imaging signs in amyloid PET are helpful to distinguish if a region is normal or abnormal. This article reviews appropriate use criteria for amyloid PET, introduces the properties of the radiopharmaceuticals, explains the algorithmic approach to interpretation with examples of normal and abnormal amyloid PET scans with MRI correlation, and provides an atlas of regional amyloid PET signs and common artifacts. RSNA, 2018.

Download full-text PDF

Source
http://dx.doi.org/10.1148/rg.2018180160DOI Listing

Publication Analysis

Top Keywords

amyloid pet
32
alzheimer dementia
12
normal abnormal
12
amyloid
9
pet
8
diagnosis alzheimer
8
appropriate criteria
8
f-labeled radiopharmaceuticals
8
signs artifacts
4
artifacts amyloid
4

Similar Publications

Objective: Focused ultrasound (FUS)-mediated blood-brain barrier (BBB) opening is safe and potentially beneficial in patients with Alzheimer's disease (AD) for the removal of amyloid-beta (Aβ) plaques. However, the optimal BBB opening intervals and number of treatment sessions for clinical improvement remain undefined. Therefore, the aim of this study was to evaluate the safety and benefits of repeated and more extensive BBB opening alone.

View Article and Find Full Text PDF

Background: Plasma biomarkers demonstrated potential in identifying amyloid pathology in early Alzheimer's disease. Different subtypes of subjective cognitive decline (SCD) may lead to different cognitive impairment conversion risks.

Objective: To investigate the differences of plasma biomarkers in SCD subtypes individuals, which were unclear.

View Article and Find Full Text PDF

Background: Urinary formic acid (FA) has been reported to be a biomarker for Alzheimer's disease (AD). However, the association between FA and pathological changes in memory clinic patients is currently unclear.

Objective: This study aims to investigate associations between FA and pathological changes across different cognitive statuses in memory clinic patients.

View Article and Find Full Text PDF

The precuneus is a site of early amyloid-beta (Aβ) accumulation. Previous cross-sectional studies reported increased precuneus fMRI activity in older adults with mild cognitive deficits or elevated Aβ. However, longitudinal studies in early Alzheimer's disease (AD) are lacking and the relationship to the Apolipoprotein-E () genotype is unclear.

View Article and Find Full Text PDF

Background: Amyloid beta (Aβ) deposition marks an early stage in the progression of Alzheimer's disease (AD), detectable in‐vivo years before symptoms emerge and targeted by recently FDA‐approved drugs. This has propelled advancements in understanding, measuring, and treating AD, paving the way for disease prevention in those at risk. However, the psychological impact of disclosing Aβ status to cognitively unimpaired individuals remains underexplored.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!